Exagen, a provider of autoimmune testing solutions, entered into an amendment to its loan and security agreement with its primary lender, an affiliate of Innovatus Capital Partners. The amended agreement provides a five-year, $27.2 million term loan at 8% interest, of which 2% is paid in-kind in the form of additional term loans.
“Innovatus has been a great partner to Exagen and we are excited about extending our relationship,” Ron Rocca, president and CEO of Exagen, said.
“We are delighted to continue our support of Exagen in its pursuit of transforming the care for patients suffering from chronic autoimmune diseases,” Claes Ekstrom, managing director at Innovatus Capital Partners, said. “We look forward to supporting the outstanding team at Exagen in their mission to improve patient outcomes and lower healthcare costs.”
